Drug manufacturer Ipca Laboratories Ltd has informed that the company has linked up with US based Heritage Pharmaceuticals Inc. with the aim to make and sell Propranolol HCI Oral tablets, used for cardiovascular treatment. 

Under the alliance, Ipca has got sanction from U.S. Food and Drugs Administration (USFDA) to manufacture and market the drug in 10, 20, 40, 60 and 80 mg strength in the US market.

According to the sources, the drug will be manufactured by Ipca and its sale will be carried by Heritage in the U.S. market. 

The source further revealed that Propranolol Tablets treats various cardiovascular related usages, including the treatment of hypertension, severe chest pain and abnormal rhythm of the heart. 

At the same time, under the strategic tie up with Ranbaxy, Ipca has got another USFDA nod to manufacture and market Metoclopramide Tablets. 

The scrip of Ipca Laboratories ended the day at Rs 510, down 0.33% on National Stock Exchange (NSE). The total volume of shares traded was 6,396 at the NSE.